Verigou E, Chatzilygeroudi T, Lazaris V, de Lastic A, Symeonidis A
Front Oncol. 2024; 14:1447001.
PMID: 39544295
PMC: 11560873.
DOI: 10.3389/fonc.2024.1447001.
Saft L
Pathologie (Heidelb). 2023; 44(Suppl 3):164-175.
PMID: 37991530
PMC: 10739577.
DOI: 10.1007/s00292-023-01272-8.
Porwit A, Bene M, Duetz C, Matarraz S, Oelschlaegel U, Westers T
Cytometry B Clin Cytom. 2022; 104(1):27-50.
PMID: 36537621
PMC: 10107708.
DOI: 10.1002/cyto.b.22108.
El Hussein S, Loghavi S
Cancers (Basel). 2022; 14(22).
PMID: 36428782
PMC: 9688198.
DOI: 10.3390/cancers14225690.
DeRosa P, Roche K, Nava V, Singh S, Liu M, Agarwal A
Curr Oncol. 2022; 29(7):4587-4592.
PMID: 35877223
PMC: 9325113.
DOI: 10.3390/curroncol29070363.
Proliferative and anti-apoptotic fractions in maturing hematopoietic cell lineages and their role in homeostasis of normal bone marrow.
Mestrum S, Vanblarcum R, Drent R, Boonen B, van Hemert W, Ramaekers F
Cytometry A. 2022; 101(7):552-563.
PMID: 35429122
PMC: 9540078.
DOI: 10.1002/cyto.a.24558.
Integration of multiparameter flow cytometry score improves prognostic stratification provided by standard models in primary myelofibrosis.
Mannelli F, Bencini S, Coltro G, Loscocco G, Peruzzi B, Rotunno G
Am J Hematol. 2022; 97(7):846-855.
PMID: 35338671
PMC: 9682857.
DOI: 10.1002/ajh.26548.
Mutant U2AF1-induced alternative splicing of H2afy (macroH2A1) regulates B-lymphopoiesis in mice.
Kim S, Srivatsan S, Chavez M, Shirai C, White B, Ahmed T
Cell Rep. 2021; 36(9):109626.
PMID: 34469727
PMC: 8454217.
DOI: 10.1016/j.celrep.2021.109626.
The potential of proliferative and apoptotic parameters in clinical flow cytometry of myeloid malignancies.
Mestrum S, Hopman A, Ramaekers F, Leers M
Blood Adv. 2021; 5(7):2040-2052.
PMID: 33847740
PMC: 8045496.
DOI: 10.1182/bloodadvances.2020004094.
Hypoplastic Myelodysplastic Syndromes: Just an Overlap Syndrome?.
Fattizzo B, Serpenti F, Barcellini W, Caprioli C
Cancers (Basel). 2021; 13(1).
PMID: 33401595
PMC: 7795441.
DOI: 10.3390/cancers13010132.
Exploring blast composition in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms: CD45RA and CD371 improve diagnostic value of flow cytometry through assessment of myeloblast heterogeneity and stem cell aberrancy.
Shameli A, Dharmani-Khan P, Luider J, Auer I, Shabani-Rad M
Cytometry B Clin Cytom. 2020; 100(5):574-589.
PMID: 33369070
PMC: 8519034.
DOI: 10.1002/cyto.b.21983.
Multilineage Dysplasia as Assessed by Immunophenotype in Acute Myeloid Leukemia: A Prognostic Tool in a Genetically Undefined Category.
Mannelli F, Bencini S, Piccini M, Gianfaldoni G, Bonetti M, Peruzzi B
Cancers (Basel). 2020; 12(11).
PMID: 33143086
PMC: 7693580.
DOI: 10.3390/cancers12113196.
Evaluation of multiparametric flow cytometry in diagnosis & prognosis of myelodysplastic syndrome in India.
Dhingra G, Dass J, Arya V, Gupta N, Saraf A, Langer S
Indian J Med Res. 2020; 152(3):254-262.
PMID: 33107485
PMC: 7881827.
DOI: 10.4103/ijmr.IJMR_924_18.
Dyserythropoiesis evaluated by the RED score and hepcidin:ferritin ratio predicts response to erythropoietin in lower-risk myelodysplastic syndromes.
Park S, Kosmider O, Maloisel F, Drenou B, Chapuis N, Lefebvre T
Haematologica. 2018; 104(3):497-504.
PMID: 30287621
PMC: 6395339.
DOI: 10.3324/haematol.2018.203158.
Editorial: A Revised Approach to the Pathogenesis and Diagnosis of Myelodysplastic Syndromes With Therapeutic Implications.
Aanei C, Campos Catafal L, Guyotat D
Front Oncol. 2018; 8:261.
PMID: 30079311
PMC: 6063204.
DOI: 10.3389/fonc.2018.00261.
The Use of Flow Cytometry in Myelodysplastic Syndromes: A Review.
Bento L, Correia R, Mangueira C, Barroso R, Rocha F, Bacal N
Front Oncol. 2017; 7:270.
PMID: 29188193
PMC: 5694750.
DOI: 10.3389/fonc.2017.00270.
Functional expression of Tim-3 on blasts and clinical impact of its ligand galectin-9 in myelodysplastic syndromes.
Asayama T, Tamura H, Ishibashi M, Kuribayashi-Hamada Y, Onodera-Kondo A, Okuyama N
Oncotarget. 2017; 8(51):88904-88917.
PMID: 29179486
PMC: 5687656.
DOI: 10.18632/oncotarget.21492.
Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions.
Valent P, Orazi A, Steensma D, Ebert B, Haase D, Malcovati L
Oncotarget. 2017; 8(43):73483-73500.
PMID: 29088721
PMC: 5650276.
DOI: 10.18632/oncotarget.19008.
Diagnostic Utility of Flow Cytometry in Myelodysplastic Syndromes.
Della Porta M, Picone C
Mediterr J Hematol Infect Dis. 2017; 9(1):e2017017.
PMID: 28293405
PMC: 5333741.
DOI: 10.4084/MJHID.2017.017.
[Optimal cut-off points of CD34 and CD117 in the differential diagnosis between hypocellular myelodysplastic syndrome and aplastic anemia].
Wang W, Zhu P, Gu J, Wang X
Zhonghua Xue Ye Xue Za Zhi. 2017; 38(1):75-77.
PMID: 28219233
PMC: 7348400.
DOI: 10.3760/cma.j.issn.0253-2727.2017.01.018.